Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XOMA 052 in FCAS, MWS, and Behcet's Disease
NCT01211977Phase 2Withdrawn
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Aug 2010
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of gevokizumab in familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and Behçet's disease (BD), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Planned start Aug 2010; status: withdrawn.
02
Drugs
gevokizumab
03
Conditions
familial cold autoinflammatory syndrome (FCAS)Muckle-Wells syndrome (MWS)Behçet's disease (BD)
Beyond the preview
Go deeper on NCT01211977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211977.